AI and RTLS platform for hospital operations, asset and staff tracking
Kontakt.io sells an AI-driven operations platform to hospitals, built on location data from Bluetooth Low Energy and Ultra-Wideband hardware streamed through Kafka into a Java/Kotlin and Spring backend on AWS and Kubernetes. Active Terraform adoption alongside GitOps, disaster-recovery and observability projects points to a hardening of infrastructure for uptime-critical clinical environments. Hiring is accelerating and split between engineering and GTM roles.
Kontakt.io, founded in 2013 and headquartered in New York, NY, provides an AI platform that helps healthcare organizations run operations more predictably. Its roots are in indoor positioning, beacons, RTLS and asset tracking, which now feed capacity, safety and decision-making use cases for hospitals. The company is privately held with 51–200 employees and currently hires in the United States. Its focus areas include reducing waste, cutting costs and improving throughput across hospital operations.
Kontakt.io runs on AWS, Kubernetes, Terraform and GitOps, with Java, Kotlin, Spring Boot, Kafka, gRPC and PostgreSQL, plus Prometheus, Grafana, Datadog and OpenTelemetry for observability.
Current projects include AI-powered automation across healthcare operations, disaster recovery and failover exercises, observability tuning, CI/CD improvements, device data integration and GTM systems.
Yes. Hiring is accelerating in the United States, led by engineering with sales and product close behind, and skewed toward senior, staff and lead-level roles.
Other companies in the same industry, closest in size
Kontakt.io's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.